Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq of human glioblastoma cells with knockdown of FGFR1 or FGFR2

ABSTRACT: RNA-Seq of human glioblastoma cells with knockdown of FGFR1 or FGFR2

PROVIDER: PRJEB64549 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR11758145.fastq.gz	Fastqsanger.gz
	ERR11758146.fastq.gz	Fastqsanger.gz
	ERR11758147.fastq.gz	Fastqsanger.gz
	ERR11758148.fastq.gz	Fastqsanger.gz
	ERR11758149.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

RNA-Seq of human glioblastoma cells with knockdown of FGFR1 or FGFR2

Project description:Human glioblastoma cell lines L0, L1, L2 (Deleyrolle et al. Brain 2010) were transduced with lentivirus vectors expressing scrambled control (shCo), FGFR1 knockdown (shFGFR1), or FGFR2 knockdown (shFGFR2) sequences. Cells were cultured in N2 medium containing EGF and stimulated with FGF2 for 48 hours prior to RNA extraction.

2023-08-29 | E-MTAB-13161 | biostudies-arrayexpress

Transcripts identified by microarray analysis that were deregulated in E14.5 Tbx18(cre/+);FGFR1(fl/fl);FGFR2(fl/fl) (Fgfr1/2cDKO) ureters

Project description:Evaluation of the transcriptional changes in E14.5 ureters upon loss of Fgfr1 and Fgfr2 in the ureteric mesenchyme.

2022-09-06 | GSE197369 | GEO

Transcripts identified by microarray analysis that were deregulated in E15.5+6d Tbx18(cre/+);FGFR1(fl/fl);FGFR2(fl/fl) (Fgfr1/2cDKO) ureter cultures

Project description:Evaluation of the transcriptional changes in E15.5+6d ureter cultures upon loss of Fgfr1 and Fgfr2 in the ureteric mesenchyme.

2022-09-06 | GSE197368 | GEO

Transcripts identified by microarray analysis that were deregulated in E13.5 Pax-2cre;Fgfr1(fl/?);Fgfr2(fl/fl) (Fgfr2cKO) ureters.

Project description:Evaluation of the transcriptional changes in E13.5 ureters upon loss of Fgfr2 (and reduction of Fgfr1) in the ureteric epithelium.

2022-01-04 | GSE178093 | GEO

RAPID RESISTANCE TO BET INHIBITORS IS MEDIATED BY FGFR1 IN GLIOBLASTOMA

Project description:Bromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have been utilized in preclinical and clinical studies. Unfortunately, BET inhibitors have not shown efficacy in clinical trials enrolling GBM patients. One possible reason for this may stem from resistance mechanisms that arise after prolonged treatment within a clinical setting. However, the mechanisms and timeframe of resistance to BET inhibitors in GBM is not known. To identify the temporal order of resistance mechanisms in GBM we performed quantitative proteomics using multiplex-inhibitor bead mass spectrometry and demonstrated that resistance to BET inhibitors in GBM treatment occurs rapidly within hours and involves the fibroblast growth factor receptor 1 (FGFR1) protein. Small molecule inhibition of BET proteins and FGFR1 simultaneously induces synergy in reducing GBM tumor growth in vitro and in vivo. Further, FGFR1 knockdown synergizes with BET inhibitor mediated reduction of GBM cell proliferation. Collectively, our studies suggest that co-targeting BET and FGFR1 may dampen resistance mechanisms to yield a clinical response in GBM.

2024-06-16 | PXD043214 | Pride

Gene expression profiling of Dermal Papilla cells isolated from wild type (WT) and Fgfr1/Fgfr2 double mutant mice during anagen (at P14 and P16) was performed by RNA-seq analysis

Project description:Gene expression analysis revealed that the DP transcriptome is altered in the Fgfr1/Fgfr2 double mutant. At P14 the expression of 188 genes was significantly altered. At P16 the expression of 1082 genes were significantly altered.

2020-08-07 | GSE155837 | GEO

RAPID RESISTANCE TO BET INHIBITORS IS MEDIATED BY FGFR1 IN GLIOBLASTOMA

Project description:Bromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have been utilized in preclinical and clinical studies. Unfortunately, BET inhibitors have not shown efficacy in clinical trials enrolling GBM patients. One possible reason for this may stem from resistance mechanisms that arise after prolonged treatment within a clinical setting. However, the mechanisms and timeframe of resistance to BET inhibitors in GBM is not known. To identify the temporal order of resistance mechanisms in GBM we performed quantitative proteomics using multiplex-inhibitor bead mass spectrometry and demonstrated that intrinsic resistance to BET inhibitors in GBM treatment occurs rapidly within hours and involves the fibroblast growth factor receptor 1 (FGFR1) protein. Additionally, small molecule inhibition of BET proteins and FGFR1 simultaneously induces synergy in reducing GBM tumor growth in vitro and in vivo. Further, FGFR1 knockdown synergizes with BET inhibitor mediated reduction of GBM cell proliferation. Collectively, our studies suggest that co-targeting BET and FGFR1 may dampen resistance mechanisms to yield a clinical response in GBM.

2023-10-23 | GSE245624 | GEO

Expression studies of FGFR1 knockdown in lymphoma

Project description:Expression studies of FGFR1 knockdown in lymphoma

| PRJNA929205 | ENA

Transcripts identified by microarray analysis that were deregulated in E14.5 Tbx18(cre/+) FGFR1(fl/fl) FGFR2(fl/fl) (Fgfr1/2cDKO) ureters

Project description:Transcripts identified by microarray analysis that were deregulated in E14.5 Tbx18(cre/+) FGFR1(fl/fl) FGFR2(fl/fl) (Fgfr1/2cDKO) ureters

| PRJNA810042 | ENA

Comparison of P18 mouse epidermis from K5-FGFR1/FGFR2 knockout and wild-type mice

Project description:Comparison of P18 mouse epidermis from K5-FGFR1/FGFR2 knockout and wild-type mice

| PRJNA436568 | ENA